SpringWorks Therapeutics Q4 2021 Earnings Report
Key Takeaways
SpringWorks Therapeutics reported no revenue for Q4 2021. R&D expenses were $29.3 million, and G&A expenses were $26.5 million. The company reported a net loss of $56.1 million, or $1.15 per share. Cash, cash equivalents, and marketable securities were $432.7 million as of December 31, 2021.
Topline analysis from Phase 3 DeFi trial expected to be triggered in the first quarter of 2022; Topline data expected to be reported during the first half of 2022.
Expanded collaboration with GlaxoSmithKline to include two new sub-studies evaluating the combination of Nirogacestat Plus BLENREP with standard-of-care multiple myeloma therapies; Initial clinical data from ongoing study expected mid-year.
Completed Enrollment in Phase 2b ReNeu Trial Evaluating Mirdametinib in Adult and Pediatric Patients with NF1-Associated Plexiform Neurofibromas.
Ended 2021 with $432.7 Million in Cash, Cash Equivalents and Marketable Securities.